(lp0
S'Albireo Pharma Inc  Moves into Overbought Territory Business Review - Mar 20, 2017 Checking on current RSI levels on shares of Albireo Pharma Inc , the 14-day RSI is currently standing at 70.53, pushing the stock into overbought territory.'
p1
aS'Albireo Pharma Inc. ALBO  Wall Street Journal - Feb 1, 2001 News Albireo Pharma Inc.ALBO. Significant News Only. 03/07/17; Press Release. Albireo to Host Conference Call and Webcast on March 14 at 8:30 a.m.'
p2
aS'Research Brokerage Views on Stellar Biotechnologies, Inc.  Albireo ... Rives Journal - 16 hours ago Stock research firms currently have a positive stance on shares of Stellar Biotechnologies, Inc. . Analysts are projecting that the stock will reach $4.00 on a short term  basis.'
p3
aS'21.71 MarketWatch - Nov 9, 2016 Albireo Pharma Inc. Watchlist CreateALBOAlert. Closed. Last Updated: Mar 20, 2017 4:00 p.m.. $ 21.71. -0.60 -2.69%.'
p4
aS'BRIEF-Albireo Pharma Inc says filed for mixed shelf offering of up to $100 mln Reuters - Dec 22, 2016 TOKYO, March 21 Asian shares clung to their 15-month highs on Tuesday while the dollar and U.S. bond yields were on the back foot on the prospects of a less-hawkish Federal Reserve policy trajectory.'
p5
aS"Albireo Completes Transaction with Biodel to Create Publicly Traded Company ... GlobeNewswire  - Nov 3, 2016 BOSTON, Nov. 03, 2016  -- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange&nbsp;...Nine stories you may have missed Thursday from the world of business - The Boston GlobeBoston's newest public company, Albireo, aims to treat kids' liver diseases - Boston Business Journal"
p6
aS'Albireo to Present at 19th Annual BIO CEO &amp; Investor Conference GlobeNewswire  - Feb 6, 2017 BOSTON, Feb. 06, 2017  -- Albireo Pharma, Inc. , a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer,&nbsp;...'
p7
aS'ALBIREO PHARMA, INC.  Files An 8-K Departure of Directors or ... Market Exclusive - Jan 27, 2017 On January 23, 2017, the Board of Directors  of Albireo Pharma, Inc. , acting upon the recommendation of the Compensation Committee of the Board , approved an increase in the annual base&nbsp;...'
p8
aS'Q1 2017 EPS Estimates for Albireo Pharma, Inc. Cut by Analyst  Chaffey Breeze - Mar 19, 2017 Albireo Pharma logo Albireo Pharma, Inc.  - Analysts at William Blair cut their Q1 2017 EPS estimates for shares of Albireo Pharma in a research report issued on Tuesday.'
p9
aS'The Analysts Anticipate Albireo Pharma, Inc.  to Post  EPS Petro Global News 24 - Mar 20, 2017 Albireo Pharma, Inc.  has been assigned a consensus broker rating score of 0.00  from the two brokers that cover the company, Zacks Investment Research reports.'
p10
a.